Teesta Agro Industries manufactures and sells chemical fertilizers, specifically Single Super Phosphate and NPK mixtures, along with sulphuric acid for agricultural use in India.
The company operates in a highly regulated, commodity-driven industry where returns on capital and net margins are persistently low, averaging below 6% and 3% respectively. There is no evidence of durable pricing power or a cost advantage that translates into superior profitability compared to the industry.
Management primarily reinvests in capacity and overhauls, such as the Chittorgarh unit and solar plants, but these investments have yet to produce meaningful improvements in return on equity. They have recently initiated a dividend after years of zero payouts, despite low cash conversion.
Five years out, the capital allocated to the Chittorgarh unit and solar projects failed to clear the cost of capital, further diluting an already abysmal return on equity. The combination of poor cash conversion and increased managerial pay drained the balance sheet, while the lack of pricing power in a regulated commodity market meant the company could not pass on rising input costs. The governance lapses—previously dismissed as minor—foreshadowed a total breakdown in internal controls, leading to a liquidity trap where reported profits never materialized as spendable cash for shareholders.
RichFakir rates Teesta Agro Industries Ltd's business quality as poor — 36/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Teesta Agro Industries Ltd is trading about 3% above our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Teesta Agro Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Teesta Agro Industries Ltd's fair value is about ₹111 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →